Perth-based Proteomics International Laboratories (ASX:PIQ) says it has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader (KOL) on diabetic kidney disease diagnostics during the ADA 79th Scientific Sessions conference in San Francisco.
The company's PromarkerD will also be presented at the conference exhibit hall.
PromarkerD is a blood test that can diagnose and predict whether a patient will develop diabetic kidney disease. It can predict the onset of diabetic kidney disease before clinical symptoms appear.
According to managing director Dr Richard Lipscombe, “The PromarkerD test can make a major difference for patients, healthcare providers and insurance companies because it could cut dramatically the number of people who are unaware they have progressive kidney disease.
"An early diagnosis will enable patients to do something about it immediately, and so reduce the potential of costly kidney dialysis."
PromarkerD was rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its independent industry report titled Biomarkers Enabling Diabetes and Obesity Management.